CLINICAL TRIALS PROFILE FOR VICTOZA
✉ Email this page to a colleague
All Clinical Trials for VICTOZA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00993720 ↗ | Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes | Completed | Hvidovre University Hospital | Phase 2/Phase 3 | 2009-10-01 | The aim of the study is to investigate the effect of Victoza (a GLP-1 receptor agonist)on insulin-dose, risk of hypoglycemia and gastric emptying rate during hypoglycemia in patients with type 1 diabetes. |
| NCT01029886 ↗ | Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes | Completed | Eli Lilly and Company | Phase 3 | 2010-01-01 | No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and other clinical benefits. The study includes a 26-week treatment period and a safety follow-up visit 10 weeks after the final study drug dose. |
| NCT01029886 ↗ | Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes | Completed | AstraZeneca | Phase 3 | 2010-01-01 | No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and other clinical benefits. The study includes a 26-week treatment period and a safety follow-up visit 10 weeks after the final study drug dose. |
| NCT01226966 ↗ | Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes | Completed | Novo Nordisk A/S | 2010-09-01 | This observational study is conducted in Europe. The aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the conditions of use of Victoza® in daily medical practice in France. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for VICTOZA
Condition Name
Clinical Trial Locations for VICTOZA
Trials by Country
Clinical Trial Progress for VICTOZA
Clinical Trial Phase
Clinical Trial Sponsors for VICTOZA
Sponsor Name
